Abstract
Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.
| Original language | English |
|---|---|
| Pages (from-to) | 73-80 |
| Number of pages | 8 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 148 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Oct 14 2014 |
Fingerprint
Keywords
- Androgen receptor
- Antiandrogens
- Cyproterone acetate
- GnRH analogs
- Metastatic male breast cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)
Cite this
Antiandrogen therapy in metastatic male breast cancer : results from an updated analysis in an expanded case series. / Di Lauro, Luigi; Vici, Patrizia; Barba, Maddalena; Pizzuti, Laura; Sergi, Domenico; Rinaldi, Massimo; Di Benedetto, Anna; Sperduti, Isabella; Shaaban, Abeer M.; Speirs, Valerie; Mottolese, Marcella; De Maria, Ruggero; Maugeri-Saccà, Marcello.
In: Breast Cancer Research and Treatment, Vol. 148, No. 1, 14.10.2014, p. 73-80.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiandrogen therapy in metastatic male breast cancer
T2 - results from an updated analysis in an expanded case series
AU - Di Lauro, Luigi
AU - Vici, Patrizia
AU - Barba, Maddalena
AU - Pizzuti, Laura
AU - Sergi, Domenico
AU - Rinaldi, Massimo
AU - Di Benedetto, Anna
AU - Sperduti, Isabella
AU - Shaaban, Abeer M.
AU - Speirs, Valerie
AU - Mottolese, Marcella
AU - De Maria, Ruggero
AU - Maugeri-Saccà, Marcello
PY - 2014/10/14
Y1 - 2014/10/14
N2 - Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.
AB - Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.
KW - Androgen receptor
KW - Antiandrogens
KW - Cyproterone acetate
KW - GnRH analogs
KW - Metastatic male breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84922074874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922074874&partnerID=8YFLogxK
U2 - 10.1007/s10549-014-3138-9
DO - 10.1007/s10549-014-3138-9
M3 - Article
C2 - 25238881
AN - SCOPUS:84922074874
VL - 148
SP - 73
EP - 80
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 1
ER -